The estimated Net Worth of Setareh Seyedkazemi is at least $351 Thousand dollars as of 15 September 2023. Setareh Seyedkazemi owns over 6,201 units of Adverum Biotechnologies Inc stock worth over $335,148 and over the last 3 years Setareh sold ADVM stock worth over $15,908.
Setareh has made over 3 trades of the Adverum Biotechnologies Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Setareh sold 6,201 units of ADVM stock worth $9,426 on 15 September 2023.
The largest trade Setareh's ever made was buying 20,000 units of Adverum Biotechnologies Inc stock on 23 May 2022 worth over $16,800. On average, Setareh trades about 3,584 units every 53 days since 2022. As of 15 September 2023 Setareh still owns at least 47,674 units of Adverum Biotechnologies Inc stock.
You can see the complete history of Setareh Seyedkazemi stock trades at the bottom of the page.
Setareh's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard, and Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include: